Compare Crispr Therapeutics AG (CRSP) vs Chevron Corp (CVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Chevron Corp — how do they compare? Crispr Therapeutics AG trades at $53.89 (market cap $5.23B), while Chevron Corp trades at $196.86 (market cap $385.77B). The key difference: Chevron Corp is far larger — about 73.8× Crispr Therapeutics AG's market cap, and Chevron Corp pays a 3.62% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | CVX | |
|---|---|---|
Market Cap | $5.23B | $385.77B |
Sector | Health | Energy |
52-Week High | $76.78 | $211.14 |
52-Week Low | $44.34 | $146.72 |
Enterprise Value | $3.65B | $414.31B |
Volume | — | 9,807,834 |
Dividend Yield | — | 3.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.83, up 0.6% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a Q2 2026 EPS beat with a loss of $0.94 versus an expected $1.19 loss, driven by surging CASGEVY sales. However, financials show deep losses, with a net income margin of -4,101.26% in 2025 and negative operating cash flow, though financing activities provided liquidity.
The outlook is mixed: strong analyst consensus (57.9% buy ratings) and a $82.67 price target reflect optimism around CASGEVY growth and pipeline catalysts, but high valuation (P/S of 466.05) and persistent cash burn pose significant risks. Investment appeal hinges on successful clinical advancements and path to profitability.
CVX trades at $194.9, up 4.47% today, with a bullish technical signal and strong analyst support. Recent earnings consistently beat expectations, with Q2 2026 EPS of $6.06 exceeding the $5.55 forecast. The company maintains solid profitability with a 9.87% net margin and 12.25% ROE, supported by a $13.8 billion investment in Argentina's Vaca Muerta shale project announced on June 2, 2026 (Reuters).
Outlook remains positive with a consensus price target of $214.25, implying 10% upside. Risks include declining revenue from $184.43B in 2025 and exposure to volatile oil prices, but high oil prices and strategic expansions provide growth catalysts. The stock offers a steady dividend of $1.78 per half-year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →
